Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.48 |
| ▸ | SAT1 | P21673 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045259 | 0.97 | CYP2C19 (0.65) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL25569446 | 0.95 | CYP2C19 (0.62) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL12319690 | 0.95 | CYP2C19 (0.67) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL19749144 | 0.92 | CYP2C19 (0.55) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL13893418 | 0.92 | CYP2C19 (0.55) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL19308992 | 0.92 | CYP2C19 (0.55) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL25565749 | 0.86 | CYP2C19 (0.45) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL23806395 | 0.84 | CYP2C19 (0.42) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL22753503 | 0.84 | CYP2C19 (0.42) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL12085575 | 0.84 | CYP2C19 (0.60) | CYP2C19MEN1GLAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022135332-A1 | STEROID CONJUGATE | 映恩生物制药（苏州）有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-4048312-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-3956495-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CYP2C19 2655/4885MEN1 1427/4885GLA 3549/4885 |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | CYP2C19 433/4885MEN1 3223/4885GLA 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.